Chronic Total Occlusion of Arteries of the ExtremitiesPROSPECTORNCT03266835
SoundBite™ Crossing System Pivotal Peripheral CTO Crossing Study
A study testing SoundBite™ Crossing System - Peripheral in people with Chronic Total Occlusion of Arteries of the Extremities, run by SoundBite Medical Solutions, Inc. at 2 sites in 2 countries.
Trial summary
This study is aimed at demonstrating the efficacy and safety of the SoundBite™ Crossing System-Peripheral. The study is intended to demonstrate that the SoundBite™ Crossing System can facilitate the passage of either devices intended to treat a chronic total occlusion (CTO) or additional crossing devices through an… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Chronic Total Occlusion of Arteries of the Extremities
- What is being tested?
- SoundBite™ Crossing System - Peripheral
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 2 sitesin 2 countries
- Study dates
- 16 Nov 2017to 18 Jan 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
General Inclusion Criteria:
- Has symptomatic chronic limb ischemia, requiring treatment of an in:frainguinal artery
- Has Rutherford Clinical Category of 2-5
- Is ≥ 18 years old
- Has life expectancy > 1 year
- Is able and willing to provide written informed consent prior to study procedure
Angiographic Inclusion Criteria:
Unless otherwise specified, the Investigator performing the procedure bases angiographic inclusion on visual determination of qualification imaging taken at time of procedure.
Subject must meet ALL the following angiographic inclusion criteria:
- Has evidence of a clinically significant de novo CTO located in a peripheral vessel below the infrainguinal ligament confirmed by angiography at time of procedure.
- Notwithstanding criteria 1, multilevel CTOs are included as long as the total length from the beginning of the most proximal total occlusion to the end of the most distal total occlusion is less than 40 cm.
- 100% stenosis by visual estimate of angiography at time of procedure.
- Has target limb with at least one patent (<50% stenosis) run-off vessel confirmed by angiography or magnetic resonance angiography at time of procedure.
General Exclusion Criteria:
- Has had a previous peripheral bypass that includes the target vessel.
- Has had a previous intervention on the target CTO (e.g., angioplasty, stent placement), including previous attempt at time of index procedure.
- History of any vascular procedure on the index limb within the last 30 days requiring clinically driven re-intervention.
- Has an active infection in the target limb.
- Subject has any planned major surgical or interventional procedure within 30 days after the study procedure.
- Has received a kidney transplant.
- Glomerular Filtration Rate (GFR) of less than 40.
- Unstable coronary artery disease or other uncontrolled comorbidity.
- Myocardial infarction or stroke within 2 months prior to baseline evaluation.
- Subject has positive pregnancy test result in women of child bearing potential or is breast-feeding.
- Participation in any study of an investigational device, medication, biologic, or other agent during study or within 30 days prior to enrollment that is either a cardiovascular study or could, in the judgment of the investigator, affect the results of this study.
- Subject in whom antiplatelet, anticoagulant therapy is contraindicated
- Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/ml or known coagulopathy.
- Known, untreated allergy to contrast agents or medications used during or subsequent to endovascular intervention. Patients with aspirin allergy that have been desensitized are not excluded.
- History of heparin-induced thrombocytopenia (HIT) that cannot be treated with direct thrombin inhibitors.
- Any thrombolytic therapy within two weeks prior to enrollment.
- Psychiatric disorder which in the judgment of the investigator could interfere with provision of informed consent, completion of tests, therapy, follow-up or general study compliance Angiographic Exclusion Criteria Unless otherwise specified, the Investigator performing the procedure bases angiographic exclusion on visual determination of qualification imaging taken up to 6 months prior to procedure and/or imaging taken at time of procedure. Subject is excluded if ANY of the following angiographic exclusion criteria is met:
- Has significant stenos is or occlusion of inflow tract ( upstream disease) unsuccessfully treated at time of index procedure or presenting symptoms such as embolism confirmed by angiography.
- Has in a native vessel, a previously stented segment separated by < 3 cm of angiographically normal vessel from the target CTO.
- CTOs lacking at least one patent target distal artery (::;SO% diameter stenosis).
- Has an acute or sub-acute intraluminal thrombus within the target vessel.
- Aneurysm distal to puncture access site at least twice the reference vessel diameter, located in the index vessel, abdominal aorta, iliac or popliteal.
- Has perforation, dissection or other injury of the access site or index vessel requiring stenting or surgical intervention prior attempting crossing of the target lesion with SoundBite™ Crossing System.
- Clinical/angiographic evidence of distal embolization in the index extremity.
Trial locations and contacts
2 sites in 2 countries.
2 sites in 2 countries
Canada1 site
CHUM-Hôtel-Dieu du Centre Hospitalier Universitaire de Montréal
Montreal, Quebec, H2W 1T8
About this study
Official title: A Multinational, Single-Arm Pivotal Study to Assess the Performance Rate Of SoundBite™ Active Wire for PEripheral Chronic Total Occlusion Recanalization (PROSPECTOR)
This study is aimed at demonstrating the efficacy and safety of the SoundBite™ Crossing System-Peripheral. The study is intended to demonstrate that the SoundBite™ Crossing System can facilitate the passage of either devices intended to treat a chronic total occlusion (CTO) or additional crossing devices through an infrainguinal CTO into the true lumen.
Read the detailed description
This is a multinational, single-arm, pivotal trial assessing the efficacy and safety of the SoundBite™ Crossing System - Peripheral. The enrollment will consist of up to 100 patients meeting the inclusion/exclusion criteria in order to obtain 90 evaluable patients for efficacy and safety analysis. The primary endpoints will be compared to literature-based performance goals to establish study success.
Objective Performance Goals (OPG) have been obtained from a literature based review. Reports published in the past 10 years were reviewed for both safety and effectiveness in crossing infrainguinal CTO. The studies reviewed generally have one primary composite safety endpoint and one primary efficacy endpoint. Some studies have performed formal hypothesis testing versus a pre-specified performance goal for one or both endpoints.
- Being tested
- SoundBite™ Crossing System - Peripheral
- Keywords
- Chronic Total Occlusion, Peripheral, SoundBite™ Crossing System, CTO, intra-luminal, Active wire, Device, Procedure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SoundBite™ Crossing System - PeripheralDevice
SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.
| Study group | Role | What they receive |
|---|---|---|
| SoundBite™ Crossing System - Peripheral | Other | This is a multinational, single-arm, pivotal trial assessing the efficacy and safety of the SoundBite™ Crossing System with subjects diagnosed with de novo infrainguinal arterial chronic total occlusion(s). Receives: Device: SoundBite™ Crossing System - Peripheral |
What is being measured
The primary outcome is the main question the study is designed to answer.
Technical Device Success
Ability to facilitate treatment of the target lesion by allowing additional crossing and/or treatment devices to cross the CTO
Measured: Day 1
Freedom from SoundBite™ Crossing System related MAEs at 30 days post procedure
MAEs defined as:
- Cardiovascular related deaths
- Unplanned, index limb amputation
- Dissection of grade C or greater that require an intervention to resolve
- Symptomatic distal embolization, defined as clinical signs or symptoms of distal emboli detected in the treated limb distal to the treated lesion after the index procedure or noted angiographically after the index procedure, and requiring mechanical or pharmacologic means to improve flow
Measured: up to Day 30
Secondary outcomes (5)
Procedural success
Achievement of Technical Success together with post-procedural patency. Post-procedural patency is defined as less then or equal to 50% residual percent diameter stenosis assessed by visual estimate at the end of revascularization procedure
Measured: Day 1
Clinical Success
Achievement of Procedural Success as well as freedom from SoundBite™ Crossing System related MAEs at 30 days
Measured: Up to Day 30
Penetration ≥ 0.5 cm
Ability of the SoundBite™ Crossing System to penetrate ≥ 0.5 cm of any segment of the CTO
Measured: Day 1
Fully traverse
Ability of the SoundBite™ Crossing System to fully traverse the CTO with entry into the distal true lumen without the need for additional guidewires and/or re-entry devices
Measured: Day 1
Freedom from any SoundBite™ Crossing System related Adverse Events
Freedom from any SoundBite™ Crossing System related Adverse Events
Measured: Up to Day 30
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Aug 2017
- Study start16 Nov 2017
- Primary completion18 Jan 2019
- Study completion18 Jan 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Total Occlusion of Arteries of the ExtremitiesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- SoundBite Medical Solutions, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- ethica Clinical Research Inc., Prairie Vascular Research Inc.
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03266835
- Sponsor's protocol ID
- NAP-PER-2017-01
- Acronym
- PROSPECTOR
- Status last verified
- Apr 2019
- First submitted
- 25 Aug 2017
- Last updated
- 25 Apr 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Apr 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multinational, Single-Arm Pivotal Study to Assess the Performance Rate Of SoundBite™ Active Wire for PEripheral Chronic Total Occlusion Recanalization (PROSPECTOR)
- ClinicalTrials.gov ID
- NCT03266835
- Acronym / sponsor ID
- PROSPECTOR / NAP-PER-2017-01
- Keywords
- Chronic Total Occlusion, Peripheral, SoundBite™ Crossing System, CTO, intra-luminal, Active wire, Device, Procedure
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- SoundBite Medical Solutions, Inc.Industry (pharma, biotech, devices)
- Collaborators
- ethica Clinical Research Inc., Prairie Vascular Research Inc.
- Study start
- 16 Nov 2017 (actual)
- Primary completion
- 18 Jan 2019 (actual)
- Study completion
- 18 Jan 2019 (actual)
- First posted
- 30 Aug 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is aimed at demonstrating the efficacy and safety of the SoundBite™ Crossing System-Peripheral. The study is intended to demonstrate that the SoundBite™ Crossing System can facilitate the passage of either devices intended to treat a chronic total occlusion (CTO) or additional crossing devices through an infrainguinal CTO into the true lumen.
Detailed description
This is a multinational, single-arm, pivotal trial assessing the efficacy and safety of the SoundBite™ Crossing System - Peripheral. The enrollment will consist of up to 100 patients meeting the inclusion/exclusion criteria in order to obtain 90 evaluable patients for efficacy and safety analysis. The primary endpoints will be compared to literature-based performance goals to establish study success.
Objective Performance Goals (OPG) have been obtained from a literature based review. Reports published in the past 10 years were reviewed for both safety and effectiveness in crossing infrainguinal CTO. The studies reviewed generally have one primary composite safety endpoint and one primary efficacy endpoint. Some studies have performed formal hypothesis testing versus a pre-specified performance goal for one or both endpoints.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| SoundBite™ Crossing System - Peripheral | Other | Device: SoundBite™ Crossing System - PeripheralThis is a multinational, single-arm, pivotal trial assessing the efficacy and safety of the SoundBite™ Crossing System with subjects diagnosed with de novo infrainguinal arterial chronic total occlusion(s). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SoundBite™ Crossing System - PeripheralSoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions. | Device | SoundBite™ Crossing System - Peripheral |
Primary outcome
Technical Device Success
Time frame: Day 1
Ability to facilitate treatment of the target lesion by allowing additional crossing and/or treatment devices to cross the CTO
Freedom from SoundBite™ Crossing System related MAEs at 30 days post procedure
Time frame: up to Day 30
MAEs defined as: * Cardiovascular related deaths * Unplanned, index limb amputation * Dissection of grade C or greater that require an intervention to resolve * Symptomatic distal embolization, defined as clinical signs or symptoms of distal emboli detected in the treated limb distal to the treated lesion after the index procedure or noted angiographically after the index procedure, and requiring mechanical or pharmacologic means to improve flow
5 secondary outcomes
Procedural success
Time frame: Day 1
Clinical Success
Time frame: Up to Day 30
Penetration ≥ 0.5 cm
Time frame: Day 1
Fully traverse
Time frame: Day 1
Freedom from any SoundBite™ Crossing System related Adverse Events
Time frame: Up to Day 30
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Apr 2019.
- Individual participant dataSharing planned: No
Related trials for Chronic Total Occlusion of Arteries of the Extremities
Not yet recruiting
Rotational Atherectomy and Drug-Coated Balloon Angioplasty With Embolic Protection for Superficial Femoral Artery Occlusions
Peripheral Artery Disease, Atherectomy in Diseased Lower Extremity Arteries
Recruiting
FastWire REvascularisation of Extremities, (For LOWer Limbs) - FREEFLOW
Chronic Total Occlusion of Artery of the Extremities
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing SoundBite™ Crossing System - Peripheral in people with Chronic Total Occlusion of Arteries of the Extremities, run by SoundBite Medical Solutions, Inc. at 2 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Technical Device Success (time frame: Day 1). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Apr 2019.